Pasar al contenido principal

INHIBICION DE SIRTUINA 2: UNA NUEVA ESTRATEGIA TERAPEUTICA PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER

SAF2017-87595-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE NAVARRA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SIRT2 Inhibition Rescues Neurodegenerative Pathology but Increases Systemic Inflammation in a Transgenic Mouse Model of Alzheimer’s Disease

  • Sola-Sevilla, N.
  • Mesa-Lombardo, A.
  • Aleixo, M.
  • Expósito, Sara
  • Diaz-Perdigón, T.
  • Azqueta, Amaya
  • Zamani, F.
  • Suzuki, T.
  • Maioli, Silvia
  • Eroli, F.
  • Matton, A.
  • Ramírez, M. José
  • Solas, Maite
  • Tordera, R. M.
  • Martín, E. D.
  • Puerta, E.
Sirtuin 2 (SIRT2) has been proposed to have a central role on aging, inflammation, cancer and neurodegenerative diseases; however, its specific function remains controversial. Recent studies propose SIRT2 pharmacological inhibition as a therapeutic strategy for several neurodegenerative diseases including Alzheimer’s disease (AD). Surprisingly, none of these published studies regarding the potential interest of SIRT2 inhibition has assessed the peripheral adverse side consequences of this treatment. In this study, we demonstrate that the specific SIRT2 inhibitor, the compound 33i, does not exhibit genotoxic or mutagenic properties. Moreover, pharmacological treatment with 33i, improved cognitive dysfunction and long-term potentiation, reducing amyloid pathology and neuroinflammation in the APP/PS1 AD mouse model. However, this treatment increased peripheral levels of the inflammatory cytokines IL-1β, TNF, IL-6 and MCP-1. Accordingly, peripheral SIRT2 inhibition with the blood brain barrier impermeable compound AGK-2, worsened the cognitive capacities and increased systemic inflammation. The analysis of human samples revealed that SIRT2 is increased in the brain but not in the serum of AD patients. These results suggest that, although SIRT2 pharmacological inhibition may have beneficial consequences in neurodegenerative diseases, its pharmacological inhibition at the periphery would not be recommended and the systemic adverse side effects should be considered. This information is essential to maximize the therapeutic potential of SIRT2 inhibition not only for AD but also for other neurodegenerative diseases. Graphical Abstract: [Figure not available: see fulltext.], Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research was funded by FEDER/Ministerio de Ciencia, Innovación y Universidades Agencia Estatal de Investigación/ Project (SAF2017-87595-R and PID2020-119729 GB-100)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SIRT2 Inhibition Rescues Neurodegenerative Pathology but Increases Systemic Inflammation in a Transgenic Mouse Model of Alzheimer’s Disease

  • Sola-Sevilla, N.
  • Mesa-Lombardo, A.
  • Aleixo, M.
  • Expósito, Sara
  • Diaz-Perdigón, T.
  • Azqueta, Amaya
  • Zamani, F.
  • Suzuki, T.
  • Maioli, Silvia
  • Eroli, F.
  • Matton, A.
  • Ramírez, M. José
  • Solas, Maite
  • Tordera, R.M.
  • Martín, E.D.
  • Puerta, E.
Sirtuin 2 (SIRT2) has been proposed to have a central role on aging, inflammation, cancer and neurodegenerative diseases; however, its specific function remains controversial. Recent studies propose SIRT2 pharmacological inhibition as a therapeutic strategy for several neurodegenerative diseases including Alzheimer’s disease (AD). Surprisingly, none of these published studies regarding the potential interest of SIRT2 inhibition has assessed the peripheral adverse side consequences of this treatment. In this study, we demonstrate that the specific SIRT2 inhibitor, the compound 33i, does not exhibit genotoxic or mutagenic properties. Moreover, pharmacological treatment with 33i, improved cognitive dysfunction and long-term potentiation, reducing amyloid pathology and neuroinflammation in the APP/PS1 AD mouse model. However, this treatment increased peripheral levels of the inflammatory cytokines IL-1β, TNF, IL-6 and MCP-1. Accordingly, peripheral SIRT2 inhibition with the blood brain barrier impermeable compound AGK-2, worsened the cognitive capacities and increased systemic inflammation. The analysis of human samples revealed that SIRT2 is increased in the brain but not in the serum of AD patients. These results suggest that, although SIRT2 pharmacological inhibition may have beneficial consequences in neurodegenerative diseases, its pharmacological inhibition at the periphery would not be recommended and the systemic adverse side effects should be considered. This information is essential to maximize the therapeutic potential of SIRT2 inhibition not only for AD but also for other neurodegenerative diseases. Graphical Abstract: [Figure not available: see fulltext.], Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research was funded by FEDER/Ministerio de Ciencia, Innovación y Universidades Agencia Estatal de Investigación/ Project (SAF2017-87595-R and PID2020-119729 GB-100).